Nasioudis Dimitrios, Chapman-Davis Eloise, Frey Melissa K, Caputo Thomas A, Witkin Steven S, Holcomb Kevin
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Gynecol Oncol. 2017 Oct;147(1):81-84. doi: 10.1016/j.ygyno.2017.07.124. Epub 2017 Jul 14.
According to the revised FIGO staging system women with ovarian carcinoma and inguinal lymph node (LN) metastases, formerly stage III, are now considered stage IVB. In this study we compare their survival to that of women with stage III and stage IV disease.
Women diagnosed with epithelial ovarian carcinoma were drawn from the Surveillance, Epidemiology, and End Results database (2004-2013). Four groups were formed: group 1 (stage IV due to positive inguinal nodes), group 2 (stage III with positive para-aortic/pelvic nodes), group 3 (stage IV with positive distant nodes) and group 4 (stage IV with distant metastases). Overall (OS) and cancer-specific survival (CSS) rates were evaluated with the Kaplan-Meier method. The log-rank test and Cox-hazard models were employed for univariate and multivariate survival analysis.
A total of 11,152 women were identified. Five-year OS for women in group 1 (n=151) was 46.3% compared to 44.9% for those in group 2 (n=4,403) (p=0.4), 32.9% in group 3 (n=642) (p<0.001) and 25.3% in group 4 (n=5,956) (p<0.001). After controlling for age, race and histology, group 1 had improved overall and cancer-specific mortality compared to groups 3 and 4 but not group 2.
Ovarian cancer patients with stage IV ovarian cancer due solely to inguinal nodal metastases have similar survival as those with pelvic/para-aortic nodal involvement and improved survival compared to those harboring distant metastases. Our findings do not support the reclassification of these patients as stage IVB.
根据修订后的国际妇产科联盟(FIGO)分期系统,卵巢癌伴腹股沟淋巴结转移的女性,以前为Ⅲ期,现被视为ⅣB期。在本研究中,我们将她们的生存率与Ⅲ期和Ⅳ期疾病女性的生存率进行比较。
从监测、流行病学和最终结果数据库(2004 - 2013年)中选取诊断为上皮性卵巢癌的女性。分为四组:第1组(因腹股沟淋巴结阳性为Ⅳ期),第2组(Ⅲ期伴腹主动脉旁/盆腔淋巴结阳性),第3组(Ⅳ期伴远处淋巴结阳性)和第4组(Ⅳ期伴远处转移)。采用Kaplan-Meier法评估总生存率(OS)和癌症特异性生存率(CSS)。对数秩检验和Cox风险模型用于单因素和多因素生存分析。
共确定11152名女性。第1组(n = 151)女性的5年总生存率为46.